Research and Development Funding and Horizon Europe Debate
Full Debate: Read Full DebateDepartment: Department for Science, Innovation & Technology
Daniel Zeichner
Main Page: Daniel Zeichner (Labour - Cambridge)Department Debates - View all Daniel Zeichner's debates with the Department for Science, Innovation & Technology
Research and Development Funding and Horizon Europe
Daniel Zeichner Excerpts(1 year, 7 months ago)
Westminster HallRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Paul Blomfield
It is good to see you again so soon, Mr Hosie. I think that, when we were interrupted in such an untimely way, I was talking about the AMRC in Sheffield. Its partnership with Boeing and Rolls-Royce has shown how universities and industry can work together effectively, and participation in Horizon and the earlier framework programmes was vital to its development.
It is not just big companies—for example, Footprint, which is a tool-making SME with hundreds of years of history in Sheffield, has been involved with several Horizon-funded projects, including as a lead industrial partner working with companies and researchers across Europe to develop new additive manufacturing processes for metal components for the aerospace sector. Its chairman, Christopher Jewitt, said of Horizon that
“it’s important to rub shoulders with other manufacturers in Europe…we are competing with the world”.
There is a lot at risk if we fail to associate with Horizon Europe.
Let me use another example. EU-funded research and collaboration laid the foundations for the University of Sheffield’s gene therapy innovation and manufacturing centre, which is now leveraging private investment to develop promising treatments for millions of patients with life-threatening illnesses.
Daniel Zeichner (Cambridge) (Lab)
Everywhere I go in Cambridge, the issue that is raised is collaboration, collaboration, collaboration. I think that that is the point that my hon. Friend is making. Does he agree that without that collaboration UK science and research will be the poorer?
Paul Blomfield
My hon. Friend is absolutely right. I will come to the point that much of the debate around Horizon is focused on the funding, but it is collaboration that is so important—not only in the way that my hon. Friend describes but, as in the case of the gene therapy innovation and manufacturing centre, in creating hundreds of highly skilled local jobs.